In recent years, many states with publicly funded health care have started using cost-effectiveness analysis (CEA) along with review of clinical data as a tool to assess the entire benefit of a brand new drug to the society and set priorities with regards to medical care budget. Cost efficiency was officially included into the Ontario drug review system in the year 1993 and the Canadian drug-review scheme in 2003.
The dilemma of using cost effectiveness has gotten increasingly controversial in recent years: that they were frequently classified as being cost effective. Costs although some just approved cancer drugs cost $3,000 to $6,000 or more for one treatment cycle. This note reviews many of the contending interests in disagreements over drug funding and dilemmas about healthcare lending decisions in the existence of limited budgets.
The Challenge of Access to Oncology Drugs in Canada case study solution
PUBLICATION DATE: December 01, 2009 PRODUCT #: 909E20-HCB-ENG
This is just an excerpt. This case is about TECHNOLOGY & OPERATIONS
Related Case Solutions & Analyses:
Rise of the Direct Subsidy Scheme: Primary Schooling in Hong Kong
Arctic Timber AB: Engineered Woods Division (A)
Ticonderoga: Inverse Floating Rate Bond
Leading Public Professional Service Organizations
Forecasting with Regression Analysis
Google Valuation
Cloud Computing at Amazon
Arup: Building the Water Cube
3P Turbo-Cross Border Investment In Brazil
Scope
